Real-World Experience with dupilumab in Severe Asthma: One year data from an Italian Named Patient Program
S. Nolasco (Catania, Italy), R. Campisi (Catania, Italy), C. Crimi (Catania, Italy), N. Scichilone (Palermo, Italy), M. Porto (Catania, Italy), G. Guarnieri (Padova, Italy), A. Papi (Ferrara, Italy), B. Beghé (Modena, Italy), P. Impellizzeri (Catania, Italy), N. Crimi (Catania, Italy)
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Nolasco (Catania, Italy), R. Campisi (Catania, Italy), C. Crimi (Catania, Italy), N. Scichilone (Palermo, Italy), M. Porto (Catania, Italy), G. Guarnieri (Padova, Italy), A. Papi (Ferrara, Italy), B. Beghé (Modena, Italy), P. Impellizzeri (Catania, Italy), N. Crimi (Catania, Italy). Real-World Experience with dupilumab in Severe Asthma: One year data from an Italian Named Patient Program. 3743
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: